Netscientific PLC (LON:NSCI) shared gained more than 10% after news that its portfolio company Glycotest has been granted a Japanese patent for its core technology for the early detection of liver disease.
Glycotest – a liver disease diagnostics company – now holds a total of six patents in Australia, the US and Japan.
The patents cover the use of over 50 unique glycoprotein biomarkers which can be used for the diagnosis of liver cancer and other life-threatening liver diseases.
“We are delighted that the Japanese patent can now be added to Glycotest’s rising number of patents which add to the breadth of the IP for its liver disease diagnostic platform,” said NetScientific chief executive François Martelet.
“These granted patents and additional pending applications put Glycotest in a strong position to further protect its proprietary technology as it continues to grow.”
Glycotest added that it expects to put out some more “good news” in the coming year with regards to its intellectual property position.
Shares were up 11% to 84p.
Story by ProactiveInvestors